Patch adhesion is more than a stickiness test. Let's take a closer look at the FDA's July 2026 final guidance, Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs.
- 4 Delivery Science Lessons For RNA Developers
- Rethinking GLP-1 Delivery Beyond The Needle
- Metabolic Interventions Improve Cancer Treatment Delivery
- FDA Rethinks Skin Sensitization Testing For Generic Transdermal And Topical Delivery Systems
- Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions
- Built To Avoid Risk: How Industry Norms Stall Drug Discovery
- Does Drug Discovery Anticipate Delivery?
- Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
From Monitoring To Action: The Future Of Autonomous Care
Explore how autonomous care could transform healthcare through smarter clinical decisions, adaptive therapies, expanded access, and greater patient independence.
-
Six Ways Regulatory Affairs Helps Turn Drug Delivery Innovation Into Reality
Explore six ways proactive planning, cross-functional collaboration, and regulatory intelligence can support stronger submissions and prepare products for evolving global requirements.
-
A Calculated Move: Putting Environmental Assessment Data To Wider Use
See how stronger data, cross-functional expertise, and earlier lifecycle analysis can help teams compare design choices, evaluate trade-offs, and identify opportunities to reduce environmental impact.
-
Building Confidence In Combination Product Development
Early compatibility testing with realistic placebo models helps mitigate formulation risks, ensuring accurate dosing, predictable injection times, and long-term stability.
-
From Early Development To Commercial Launch: An End-To-End Partnership
Bringing a critical therapy to market takes early coordination. See how strategic planning helped accelerate an oncology therapy from clinical development to patients.
-
Unlocking Higher Complex Capsule Yields Through More Efficient Manufacturing
Boost complex capsule output by 3–7% per batch with targeted process optimization, without formulation changes, extra batches, new equipment, or regulatory submissions.
-
Turning A "Brick Dust" Compound Into A Clinically Viable Oral Formulation
Advanced wet milling and particle stabilization improve solubility, enhance bioavailability, and support scalable manufacturing for complex oral drug development programs.
-
Successful Tech Transfer Plans Ensured On-Time Launches
Successful technology transfers require proactive engineering and rigorous assessments to address equipment challenges, protect product integrity, and keep launches on schedule.
-
Managing Risks With Potent Pharmaceutical Products
Manufacturing potent medications safely requires specialized containment, toxicology expertise, and strict contamination controls to ensure compliance, product quality, and worker safety.
-
Is Your API Right For A Soft Gel Capsule?
Soft gel delivery systems can enhance bioavailability, enable controlled release, support combination dosing, and handle potent compounds while improving stability and patient adherence.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
Container Closure Systems For Biosimilars: Is There Regulatory Difference?
In this article, Fran DeGrazio discusses the FDA’s draft guidance on container closure systems for biosimilar products. She highlights key takeaways and offers recommendations on implications that developers of biosimilar pharmaceutical products should consider in areas such as quality, testing, and documentation.
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts.

